L2M NSERC - A liquid biopsy blood test for breast cancer detection

L2M NSERC - 用于乳腺癌检测的液体活检血液测试

• 批准号: 576550-2022
• 负责人: Mueller, ChristopherCRM
• 金额: $ 1.46万
• 依托单位: Queen's University
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=746473
• 关键词: L2M; NSERC; liquid; biopsy; blood

The key to treating cancer patients effectively largely depends on accurate and timely diagnosis; a process that can yield important clues about the stage of cancer, the tumour's molecular signature, where it is likely to spread, and the prognosis for the patient. The current gold standard methods used to diagnose cancers are based on image analysis, followed by surgical biopsies - a highly invasive form of molecular testing. For patients, this process is often painful, distressing, and does not guarantee accurate results. For more than a decade, emerging non-invasive techniques to analyze tumour material are fundamentally changing the future of cancer care. Liquid biopsies assess analytes in the bloodstream, such as circulating tumour cells (CTCs) or components of CTCs such as circulating tumour DNA (ctDNA). Liquid biopsies are increasingly recognized as having value for cancer diagnosis and clinical management of many cancers. In addition, they are far superior to the alternative - tissue biopsies, where tissue samples are not always representative of the overall tumour heterogeneity. Furthermore, they provide more accurate information about cancer progression, are more economical and affordable, and do not require a team of specialists (i.e., surgeons). Here, we present mDETECT, a second-generation liquid biopsy specifically aimed to provide clinical management of all subtypes of metastatic breast cancer. The superiority of mDETECT's technology over other liquid biopsies is it encompasses sequencing of patent-protected methylation regions across ctDNA with high precision and sensitivity and can be used in almost all patient populations. The objective of this proposal is to assess the use of mDETECT in conjunction with or in lieu of traditional gold standards of assessing cancer therapy effectiveness. We are looking to analyze the feasibility of marketing mDETECT and gauging the interest of health care providers and insurance bodies.

有效治疗癌症患者的关键在很大程度上取决于准确和及时的诊断;这一过程可以产生有关癌症阶段，肿瘤分子特征，可能扩散的地方以及患者预后的重要线索。目前用于诊断癌症的金标准方法是基于图像分析，然后是手术活检-一种高度侵入性的分子检测形式。对于患者来说，这个过程往往是痛苦的，令人痛苦的，并不能保证准确的结果。十多年来，分析肿瘤材料的新兴非侵入性技术正在从根本上改变癌症护理的未来。液体活检评估血流中的分析物，例如循环肿瘤细胞（CTC）或CTC的组分，例如循环肿瘤DNA（ctDNA）。液体活检越来越被认为对癌症诊断和许多癌症的临床管理具有价值。此外，它们远远上级替代组织活检，其中组织样本并不总是代表整体肿瘤异质性。此外，它们提供关于癌症进展的更准确的信息，更经济和负担得起，并且不需要专家团队（即，外科医生）。在这里，我们提出了mDETECT，第二代液体活检，专门旨在提供转移性乳腺癌的所有亚型的临床管理。mDETECT技术优于其他液体活检的优势在于，它包括跨ctDNA的专利保护甲基化区域的测序，具有高精度和灵敏度，并且可以用于几乎所有患者人群。本提案的目的是评估mDETECT与评估癌症治疗有效性的传统金标准联合使用或替代传统金标准的使用。我们希望分析营销mDETECT的可行性，并衡量医疗保健提供者和保险机构的兴趣。